For patients with advanced disease, our medical oncology team offers breakthrough clinical trials using new combinations of chemotherapy, immunotherapy, and novel targeted agents. Our team has national and international leadership in clinical trials for prostate, bladder, and kidney cancer.
Patients of the Prostate and Urologic Cancers Program at Smilow Cancer Hospital benefit from a comprehensive, disease-based multispecialty team. Our research efforts are rooted in clinical excellence and our patients benefit from a cutting-edge multidisciplinary approach to treating cancers of the genitourinary tract, including cancers of the prostate, bladder, kidney, ureters, testis, and penis.
This multidisciplinary team collaborates and coordinates each step of a patient’s care including diagnosis, evaluation, and treatment. The team provides a complete range of standard treatments, as well as medical and surgical approaches not found elsewhere in Connecticut.
Specialties involved include medical oncology, radiation oncology, surgical oncology, pathology, and diagnostic imaging. Physicians meet regularly to discuss every patient's care and to develop a comprehensive treatment plan unique for each patient, in consultation with the patient's referring physician.
Yale Urologic Surgery is a referral center for all malignancies of the testes, bladder, prostate, and kidney. Laparoscopic and robotic surgical options are available to patients, in addition to traditional surgical techniques.
Patients who are cared for through the Prostate and Urologic Cancers Program and need radiation therapy as a component of their prescribed treatment, can feel confident that they are receiving the highest quality care from the most experienced team of radiation oncologists in Connecticut.
Smilow Cancer Hospital offers the only program in Connecticut that uses a novel technique to perform targeted biopsies of the prostate.
Yale Pathology provides detailed analysis of tumor samples to aid in diagnostics of challenging tumor types and to allow for personalized treatment plans based on the pathology of each individual tumor.